Project Grant R01HL171111
Award Date
7/1/24
Completion Date
4/30/28
Dollars Obligated
$2.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40536, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $1,398,770.00 to The University of Kentucky Research Foundation to investigate the role of serum amyloid A (SAA) in sepsis-induced acute lung injury and mortality. The key objectives are to: 1) test the hypothesis that SAA mediates the resolution of sepsis by impeding neutrophil accumulation in injured lungs and identify the...
The federal Project Grant award R01HL176322, totaling $1,485,606.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The purpose of the grant is to study the role of lipoprotein(a) (Lp(a)) in increasing the risk of atherosclerotic cardiovascular disease (ASCVD) among people living with HIV (PWH). The project aims to: 1) establish Lp(a)-specific ASCVD risk thresholds in PWH, 2) explore mechanisms by which...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research program (CFDA 93.837), aims to determine whether inducing the protein RECK can serve as a novel therapeutic approach to prevent the development and progression of atherosclerosis. The $646,106 award will fund research at Tulane University to investigate how RECK overexpression in vascular smooth muscle cells and macrophages can inhibit inflammation, promote...
This Project Grant award of $238,620.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of protein kinase C epsilon (PKCε) in regulating inflammation and resolution in the context of atherosclerosis. The key objectives are to test the hypothesis that myeloid-specific deletion of PKCε exacerbates atherosclerosis by disrupting the balance between inflammation and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $100,325.00 to Vanderbilt University to support research on the critical role of the protein CAMK4 in regulating inflammation resolution and trained immunity in atherosclerosis. The primary aims of the project are to: 1) Investigate how trained immunity in myeloid cells impairs efferocytosis, the clearance of apoptotic cells, thereby...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $304,119 to Endomimetics LLC to develop innovative in vitro assays for screening atherosclerosis drug efficacy and cytotoxicity. The project aims to revolutionize atherosclerosis research by creating an automated, highly precise approach for fabricating 3D nanomatrix vascular sheets and vascular sheets with atherosclerosis. This...
This Project Grant award of $2,070,048 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports a comprehensive investigation of the cellular and molecular mechanisms regulating atherosclerotic plaque stability and destabilization. The award aims to advance the understanding of macrophage functions, inflammatory signaling pathways, and their interactions with vascular stromal cells in order to identify novel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $381,250 to Clemson University to investigate the potential atheroprotective impact of the ABC transporters ABCA1 and ABCG1 in vascular smooth muscle cells. The research aims to determine if increasing the expression of these cholesterol efflux transporters in vascular smooth muscle...
This federal Project Grant award for $559,893.00, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the RSPO2-LGR4 signaling pathway in regulating arterial lymphangiogenesis, vascular smooth muscle cell phenotypic changes, and atherosclerosis development. The research aims to determine the functional impact of vascular smooth muscle cell-derived RSPO2 on arterial...
This Project Grant award, with a total funding amount of $503,637, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the mechanisms of thrombosis, or blood clot formation, associated with COVID-19 infection. The research aims to understand how the acute COVID-19 infection and subsequent post-acute sequelae (PASC) can lead to the formation of microclots, which can cause...